Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Memantine nitrate - Guangzhou Magpie Pharmaceuticals

Next Previous
Drug Profile

Memantine nitrate - Guangzhou Magpie Pharmaceuticals

Alternative Names: MN 08

Latest Information Update: 24 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Magpie Pharmaceuticals
  • Class Amines; Analgesics; Antidementias; Antiglaucomas; Antiparkinsonians; Antispastics; Antitussives; Eye disorder therapies; Nitrates; Nootropics; Organic bridged compounds; Small molecules; Vascular disorder therapies
  • Mechanism of Action Nicotinic receptor antagonists; Nitric oxide donors; NMDA receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Pulmonary arterial hypertension
  • Discontinued Glaucoma; Vascular dementia

Most Recent Events

  • 21 Jan 2025 Guangzhou Magpie Pharmaceuticals received investigational new drug (IND) approval from the US FDA
  • 21 Jan 2025 Guangzhou Magpie Pharmaceuticals plans to initiate a phase I trial for idiopathic pulmonary arterial hypertension in the US
  • 02 May 2024 Guangzhou Magpie Pharmaceuticals completes a phase I trial for Pulmonary arterial hypertension (In volunteers) (PO, Tablet), prior to April 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top